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Background: Patients in chronic somatic diseases are often accompanied with depression and anxiety, remission of
which may be observed in the third or fourth week after applying common antidepressant medications. We
investigate the efficacy and safety of sertraline plus deanxit on patients with depression and anxiety in chronic
somatic diseases.
Methods: 75 Patients who met the criteria were randomly assigned to deanxit group or placebo group: sertraline
(75 mg/day) plus deanxit (one piece/day) (N = 38), or sertraline (75 mg/day) plus placebo (one piece/day) (N = 37)
for 2 weeks, both groups received sertraline (75 mg/day) in the following 2 weeks. Changes from baseline to day 4,
day 8, day 15, and day 29 in Hamilton Rating Scale for Depression (HAM-D) and Hamilton Rating Scale for Anxiety
(HAM-A) total scores were the efficacy measures. Adverse events were monitored and registered systematically
during the trial.
Results: Response rates for HAM-D scores in deanxit group and placebo group were significantly different on day 8
(55.26% ± 2.56% VS 24.32% ± 2.19%, p = 0.006) and day 15(78.95% ± 3.89% VS 40.54% ± 4.18%, p = 0.001), while no
statistical differences were observed on day 4 and day 29. Respectively, response rates for HAM-A scores on day 4
(34.21% ± 2.21% VS 8.11% ± 1.37%, p = 0.006), day 8 (57.89% ± 3.56% VS 18.92% ± 2.68%, p = 0.001) and day 15
(78.95% ± 4.37% VS 43.24% ± 4.68%, p = 0.002), favoring the deanxit group. However, HAM-A scores were not remarkably
different at the end point. The overall safety profile of both groups was favorable with no distinct differences.
Conclusions: The efficacy was exhibited in the deanxit group, with evidence for similar safety. The rapid onset of
sertraline plus short-term deanxit indicated that it might be an inspiring strategy to manage depression and anxiety
within the first two weeks in chronic somatic diseases.
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Patients are notably affected by complications in chronic
diseases predominantly mediated by social determinants
of health, suffering discomfort for a long time [1,2]. De-
pression and anxiety are highly prevalent in persons with
chronic somatic diseases such as diabetes, hypertension,
heart disease, chronic bronchitis, neurological diseases,
and significantly associate with physical health [3]. Simi-
larly, individuals with depression and anxiety tend to at* Correspondence: 13719438236@126.com
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unless otherwise stated.higher morbidity risks of the above mentioned chronic
physical conditions [4]. Mood disorders exert a substan-
tial impact on the health-related quality of life, the func-
tioning and mortality of persons with chronic somatic
diseases [5-7]. The comorbidity of depression and anx-
iety disorders is commonly unrecognized and untreated
[7], as a result of which leads to somatic symptoms ex-
acerbating [7,8], complications worsened [9] as well as
compliance weakened [10]. With identification and med-
ical management, patients suffering psychiatric disorders
can have symptoms relieved, thus optimal health out-
comes may be catalyzed [11].This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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reuptake inhibitors and serotonin-specific reuptake in-
hibitor (SSRIs) class, displays a rather beneficial balance
between efficacy and acceptability in the acute-phase
treatment of adults with major depression. Referring to
a meta-analysis of 12 new-generation antidepressants,
the cumulative probabilities of efficacy and acceptability
of sertraline are 20.3% and 21.3% [12]. Randomized clin-
ical trials have indicated that the sertraline is an effica-
cious treatment for anxiety and depressive disorders,
along with low fatal toxicity in a good tolerability profile
[13]. However, responses can be observed only 2 or
3 weeks later, even in a longer period of time when anti-
depressant drugs are prescribed [14]. Patients accom-
panied by depression and anxiety in chronic disease
have poor compliance, even abandon treatments. Thus,
there becomes an essential event to manage the symp-
toms of depression and anxiety as soon as possible, espe-
cially in the first two weeks.
Deanxit, a mixture of melitracen (10 mg) and flupen-
tixol (0.5 mg), of which agents are accordingly a kind of
tricyclic antidepressant and classical antipsychotic compo-
nent, has been proven a rapid onset with both anxiolytic
and antidepressant properties in low doses [15]. The bio-
logical half-life of flupentixol is about 35 hours and meli-
tracen is about 19 hours, and the drugs show synergistic
effect on therapeutic administration and antagonistic
effect on adverse reaction. The combination of two psy-
choactive agents which has antidepressant properties is
designed for short-term usage only. According to pub-
lished evidences, melitracen/flupentixol combination is
the most frequently prescribed compound on the basis of
defined daily doses in China [16]. Deanxit can improve
mood illness to some extent when prescribed in low dose
for a short period of time, thus compensating the shortage
of delayed response of sertraline. More generally, during
the no response time for at least two weeks, deanxit is
well tolerated.
Currently, consensus had been reached worldwide that
early antidepressant treatments and timely eradication
of the emotional disorder should come to realization
imminently, therefore in which context, we designed a
placebo-controlled study to assess the efficacy and safety
of short-term combination of deanxit in the acute treat-
ment on depression and anxiety in patients with chronic
diseases. Basing on the therapeutic onset and tolerability,
we employed a relatively conservative approach that pre-
scription of deanxit only for the first 2 weeks in this
study. To the best of our knowledge, controlled clinical
studies in this design proposal were fairly rare.
As well as investigation of efficacy and safety of Dean-
xit, whether sertraline could acts rapidly was tested. We
assumed that sertraline plus deanxit group would estab-
lish superiority versus sertraline plus placebo group interms of efficiency and response rates in a short thera-
peutic period with equivalent safety.
Methods
This 4-week, randomized, double-blind, placebo-controlled
study was conducted from August 2011 to February 2014
at Sun Yat-sen Memorial Hospital of Sun Yat-sen University
and Guangdong General Hospital. The project was regis-
tered by Chinese Clinical Trial Registry (Registration num-
ber: ChiCTR-TRC-11001732) on 25 November 2011.
Patients
Patients were recruited from inpatients or outpatients in
Guangdong General Hospital and Sun Yat-sen Memorial
Hospital of Sun Yat-sen University. Patients either males
or females who were aged from 20 to 75 years and suf-
fered from chronic somatic diseases meeting the DSM-
IV criteria for depression and anxiety were eligible for
inclusion. Moreover, the intent-to-treat patients were re-
quired to have a score > 20 on HAMD and score >14 in
HAMA at the time of screening. Patients were excluded
if they suffered from acute diseases or severe mental ill-
nesses that could confuse assessment of depression and
anxiety. The other exclusion criteria included the history
of epilepsy; the current treatment with antidepressants or
antianxiety medications; the serious heart disease or ser-
ious hepatic disease or serious renal disease; language dif-
ficulties including dyslexia; pregnant or lactating women.
Ethics
Ethical approval was obtained from each of the two sites.
The project was approved by the Ethical Committee of
Sun Yat-sen Memorial Hospital, Sun Yat-sen University,
Guangzhou, China (approved number: 201005), and in
accordance with the Helsinki Declaration of 1975. All
patients provided written informed consent before enter-
ing the study.
Study design
This study included 3 phases: a 1-week screening period;
a 4-week, randomized, double-blind, placebo-controlled
treatment period; followed by a 2-week follow-up
period. Eligible patients were divided into two groups
by randomization.
Patients received sertraline at a dosage of 75 mg/day
plus deanxit (melitracen 10 mg + flupentixol 0.5 mg) or
placebo at one piece every morning for 2 weeks, then both
groups received only sertraline treatment at a dosage of
75 mg/day for the next 2 weeks. Tablets of placebo were
identical in appearance compared with deanxit. After the
end of the double-blind treatment period, the follow-up
for 2 weeks were conducted in all patients.
This study medication was offered by the hospital phar-
macy without signs of content. The allocation of treatment
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Treatment compliance depended on retrieved tablet
amounts at each interview. The compliance of < 90% de-
fined as discontinuation. During the whole experimental
process, patients were also taking matching medications
for their chronic somatic diseases.
Depression and anxiety severity assessments
The Hamilton Rating Scale for Depression (HAM-D)
with 24 items (9 items were defined from 1 to 2, 1 item
was defined from 0 to 2, and 14 items were defined from
0 to 4) was used for assessing the severity of depression,
and the Hamilton Rating Scale for Anxiety (HAM-A)
with 14 items (each item from 0 to 4) was applied for
measuring the severity of anxiety.
The measurements of HAM-D and HAM-A were tested
at baseline and before taking medication on day 1, day 4,
day 8, day15, and day 29 in two groups. Scales were man-
aged by two trained physicians.
Treatment effect assessment
Score-reducing rate, expressed as (pre-treatment score
of HAMD/HAMA – after-treatment score of HAMD/
HAMA)/ pre-treatment score of HAMD/HAMA, was
used to evaluate the treatment effect. According to clin-
ical cure and improvement standards, the criteria of
curative effect were as follow: score-reducing rate > 75%
was recovery, 50 ~ 75% meant significant improvement,
25% ~ 49% stood for improvement and <25% as ineffect-
iveness. We defined response rate as the percentage of
patients who had score-reducing rate ≥25% in the group.
Safety and tolerability measures
The safety and tolerability of sertraline and deanxit were
mainly detected by observing and reporting adverse events
(AEs). Vital signs measurements (blood pressure, respir-
ation rate, and pulse rate), cardiogram test and clinical
laboratory tests (hematology, chemistry, and urinalysis)
were used for additional safety reference.
Statistical analysis
Two independent sample t-tests were performed to
compare the difference between the characteristic of two
groups. Chi square test was used to compare the differ-
ence of treatment efficiency. All analyses were con-
ducted using SPSS version 16.0. Significance tests were
2-tailed and managed at the 0.05 significance level.
Results
Patient recruitment and allocation
As shown in Figure 1, recruitment and allocation of pa-
tients were summarized. 120 patients were assessed for
eligibility; however, 42 patients were excluded from the
study. 1 patient dropped out from deanxit group and 2patients dropped out from placebo group. At last, only
75 patients were available for analyzed after the end
phase of the study, of which 38 patients in deanxit group
and 37 patients in placebo group.
Patient disposition and characteristics
The baseline characteristics of the patients (n = 75) were
outlined in Table 1. There were no significant differences
in age, gender, BMI and employment status of the pa-
tients between deanxit group and placebo group.
Baseline scores of HAMD and HAMA were tested to
value the situation of depression and anxiety. Deanxit
group showed 31.6 ± 4.9 score on HAMD and placebo
group showed 33.3 ± 5.1 score on HAMD, which meant
all the patients were in depression and the differences be-
tween the two groups were not significant (p > 0.05). The
differences of baseline score on HAMA between deanxit
group (22.39 ± 4.3) and placebo group (23.0 ± 4.5) also
showed no significance (p > 0.05).
Treatment effect of depression
As was shown in Figure 2, response rates on depression
increased in both two groups as time went on. Response
rates on HAMD in deanxit group on day 4, day 8, day 15,
and day 29 were 18.42% ± 1.23%, 55.26% ± 2.56%, 78.95% ±
3.89%, and 84.21% ± 1.86%, and in placebo group were
10.81% ± 1.08%, 24.32% ± 2.19%, 40.54% ± 4.18%, and
75.68% ± 1.95%. The differences were significant on day 8
(p = 0.006) and day 15 (p = 0.001), whereas, the two
groups displayed no statistically significant differences on
day 4 and day 29 (p > 0.05).
Treatment effect of anxiety
As was shown in Figure 3, as the trial continued, re-
sponse rates on HAMA of two groups both increased.
Response rates on HAMA in deanxit group on day 4,
day 8, day 15, and day 29 were 34.21% ± 2.21%, 57.89% ±
3.56%, 78.95% ± 4.37%, and 86.84% ± 2.12%, and in pla-
cebo group were 8.11% ± 1.37%, 18.92% ± 2.68%, 43.24% ±
4.68%, and 78.38% ± 3.16%. The differences were enor-
mous on day 4 (p = 0.006), day 8 (p = 0.001) and day 15
(p = 0.002). However, the two groups showed no signifi-
cant differences on day 29 (p > 0.05).
Adverse reactions
Table 2 indicates that the total adverse event cases in
deanxit group were 10 and in placebo group were 11.
The two groups both had adverse events such as dry
mouth, dizziness, sleeping disorder. However, only dean-
xit group observed 1 case of mild limb rest tremor. Most
of these adverse events occurred in the first week of
therapy, and disappeared within a week without any cor-
responding treatment.
Figure 1 CONSORT flow chart of participants through each phase in the study.
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This study assessed the efficiency and efficacy of deanxit
used as an adjuvant for short duration combining a
SSRIs agent. Response rates on depression and anxiety
increased remarkably for patients receiving deanxit, indi-
cating deanxit is superior versus placebo during the early
treatment period, though at endpoint no prominent dif-
ferences in aspect of efficacy between the two groups
were observed. At the same time, the antidepressant ef-
fect of SSRIs agent was confirmed to some extent.
SSRIs achieved outstanding advantages in the pharma-
cological treatment of depression with a high selectivity
of molecular target [17,18], and had become the most
frequently prescribed class of antidepressant drugs in
China [16]. Furthermore, attentions of clinicians should
be drawn to the delay of two or three weeks before clin-
ical onset, in case that clinical application of SSRIs
would be weakened without notice of the response speed
[19]. While aimed to achieve of optimal antidepressant-
induced improvement of depressive symptoms, it was
widely accepted that patients should spend a long time
ranging from 6 to 12 weeks [20]. What was worse, depres-
sion often combined with other psychiatric disorders, in
particularly anxiety disorder [21], leading to much poorer
compliance of patients. Hence, it was crucial to manageboth depression and anxiety as soon as possible in patients
with chronic diseases within the first 2 to 3 weeks.
The results of the current randomized, double-blind
study indicated that the sertraline plus deanxit had bet-
ter efficacy in treating depression and anxiety symptoms
at the first 2 weeks of the study period, compared with
the sertraline plus placebo group, which might contrib-
ute greatly to clinical application for worthwhile notice.
The antidepressant efficacy of sertraline in the current
study was consistent with the previous studies [13,22].
Moreover, it has been reported that diabetes-related self-
efficacy may be improved by sertraline in patients with
T2DM [23] and the depression-free interval following
recovery from major depression was prolonged by main-
tenance therapy with sertraline [24,25]. Sertraline, the
antidepressant mechanism of which including altering the
functional connectivity of the hypothalamus-anchored
resting brain network [26], achieved superior effectiveness
in Alzheimer patients on depressive, cognitive, and behav-
ioral symptoms [25]. Newly, Sertraline has been investi-
gated to exhibit a promising anti-inflammatory effect
by increasing anti-inflammatory cytokine interleukin-10
(IL-10) while suppressing interleukin-6 (IL-6), tumor
necrosis factor-alpha (TNF-α) [27,28]. Though, several
chronic diseases link closely with systemic, low-grade
Table 1 Patients characteristic
Variable Sertraline plus deanxit Sertraline plus placebo p value
(N = 38) (N = 37)
Age(yr)
Mean ± SD 62.8 ± 13.1 61.5 ± 13.3 NS
Gender(%)
Male 13(34.2%) 15(40.5%) NS
Female 25(65.8%) 22(59.5%) NS
BMI(body mass index)
Mean ± SD 28.3 ± 4.1 28.0 ± 4.3 NS
Employment status
Employed 14(36.8%) 12(32.4%) NS
Unemployed 24(63.2%) 25(67.6%) NS
Categories of chronic diseases
Single hypertension 7 7 NS
Single diabetes 8 8 NS
Single chronic headache 6 5(droup out = 1) NS
Single Parkinson’s disease 5(droup out = 1) 6 NS
chronic obstructive pulmonary diseases 5 5 NS
co-morbidity two or more chronic somatic disease 8 7(droup out = 1) NS
Baseline score of HAMD
Mean ± SD 31.6 ± 4.9 33.3 ± 5.1 NS
Baseline score of HAMA
Mean ± SD 22.39 ± 4.3 23.0 ± 4.5 NS
Notes: NS = No Significant.
Figure 2 Change of total effective rate on depression from baseline in two groups. Date represented Mean ± SEM. * means P < 0.05.
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Figure 3 Change of total effective rate on anxiety from baseline in two groups. Date represents Mean ± SEM. * means P < 0.05.
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peutic effect on some chronic diseases independent of
antidepressant and in that case, studies in the association
between sertraline and chronic somatic diseases will be
warranted in future.
The effect of short term deanxit (melitracen 10 mg +
flupentixol 0.5 mg) was viewed to make a contribution
to the improvement during the early treatment period.
Melitracen was a bipolar thymoleptic with activation
properties, exerting effects on both depression and anx-
iety, which was similar to imipramine and amitriptyline.
In addition, tolerability of melitracen was improved with
a somewhat faster onset of action. Flupenthixol acting
as antagonists at various dopamine (D1-D5), serotonin
(5-HT2), adrenaline (α1), and histamine (H1) receptors,
specifically antagonizes D1 and D2 receptors, thus typically
playing an essential role of antipsychotic without affecting
the muscarinic acetylcholine receptors [30]. Compared
with amitriptyline, flupenthixol could significantly improveTable 2 Adverse events comparison between deanxit
group and placebo group(%)
Adverse events Sertraline plus
deanxit (n = 38)
Sertraline plus
placebo (n = 37)
Dry mouth 3(7.9%) 2(5.4%)
Dizziness 2(5.3%) 3(8.1%)
Sleep disorder 1(2.6%) 2(5.4%)
Mild limb rest tremor 1(2.6%) 0(0%)
Dry mouth and Dizziness 3(7.9%) 2(5.4%)symptoms of patients with depression at low doses with a
rapid onset of action [31,32]. According to a clinical trial
aimed at short-term treatment of functional dyspepsia, pa-
tients without depression or anxiety received melitracen
plus flupenthixol showed good clinical responses with
favorable tolerance [15]. As flupentixol/melitracen was ad-
juvant for 2 weeks of treatment in patients with gastro-
esophageal reflux disease who had developed emotional
disorder, both gastroesophageal-reflux symptoms and psy-
chiatric symptoms were remarkably better than those in
the monotherapy group [33]. The exact mechanism of a
rapid onset of action and better effect on sertraline plus
deanxit group was still unclear. Deanxit may act as a
kind of potentiator of sertraline. Our results revealed that
discontinuing deanxit 2 weeks later, the efficiency of
sertraline plus deanxit group was still higher than control
group, although not reaching statistical significance. There-
fore, more researches should be done to verify whether the
role of deanxit itself for improving depression and anxiety
or the interaction with sertraline, result in that sertraline
exerted its effect more quickly and efficaciously. In addition,
the issue that whether the two drugs had combined effect
should be investigated further.
Adverse events reported previously were mild in both
groups. Sertraline plus deanxit were relatively safe and
well tolerated. Patients received sertraline plus deanxit
exhibited non-significantly higher rates, and there was
one person existing mild limb rest tremor while symp-
toms vanished without relevant treatment. In the whole
of safety profile, long-term use of deanxit might develop
tardive dyskinesia and tardive akathisia, which should be
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without delay, thus avoiding severe adverse reaction in
movement [34].
The limitations of this study included the relatively
small number of patients, the short duration of the treat-
ment, and the single-centre nature of the study. This study
recruited only five kinds of chronic diseases, which might
not stand typically for the whole. What was more, as a re-
sult of the small samples, we could not divided eligible pa-
tients by stratified randomization according to various
categories of chronic somatic diseases. In addition, almost
all of patients with chronic diseases took corresponding
medicine, which might interact with sertraline or deanxit
and confuse the effects. The results of this 4-week trial
could not generalize to longer periods of treatment, hence
further large scale and cross-sectional study in rigorously
designed would be warranted due to the limited subjects
as well as a variety of chronic diseases.
Conclusion
This controlled study demonstrated a noteworthy effect of
sertraline plus short-term deanxit in the management of
depression and anxiety in patients with chronic diseases
within the first two weeks. It may be a potentially useful
therapeutic strategy for treatment of mental illnesses when
combining deanxit with sertraline in clinical practices.
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